文献速递神经肿瘤

凸面、矢状窦旁和大脑镰脑膜瘤的生长风险分类与典型生长速度:一项回顾性队列研究

Growth risk classification and typical growth speed of convexity, parasagittal, and falx meningiomas: a retrospective cohort study.
PubMed 文献 · J Neurosurg · 2022-09-16

该回顾性队列研究纳入313例影像学怀疑凸面、矢状窦旁或大脑镰脑膜瘤患者,基于性别、年龄和T2加权MRI信号强度分为极高生长、高生长和低生长三组,计算相对生长率(RGR)和年体积变化(AVC),并展示5年后可能达到的肿瘤体积。

要点

  • 全队列中位RGR为6.1%(IQR 2.4%-16.0%),中位AVC为0.20(IQR 0.04-1.18)cm³/年。
  • 极高生长组中位RGR为17.5%、AVC为1.05 cm³/年,低生长组分别为3.4%和0.04 cm³/年,组间差异显著(p < 0.001)。
  • 极高生长组5年内典型体积增加2.24倍或5.24 cm³,低生长组即使随访5年体积变化也很小。

核心结论

  • 首次仅针对凸面、矢状窦旁和大脑镰脑膜瘤计算了典型肿瘤生长速度,并基于客观指标展示了这些部位许多病变5年后可能达到的肿瘤体积。
  • 作者认为这些结果可能使临床医生通过判断病变是否偏离典型生长速度范围来轻松识别需要频繁随访或早期治疗的病变,类似于儿童的生长曲线图。

研究设计与样本

  • 回顾性研究,纳入作者所在机构影像学怀疑凸面、矢状窦旁或大脑镰脑膜瘤的患者。
  • 通过间隔超过3个月的MRI计算相对生长率(RGR)和年体积变化(AVC)。
  • 基于性别、年龄和T2加权MRI信号强度将病例分为极高生长组、高生长组和低生长组。
  • 共分析313例病例的数据。

主要发现

  • 全队列中位RGR为6.1%(IQR 2.4%-16.0%),中位AVC为0.20(IQR 0.04-1.18)cm³/年。
  • RGR在性别(p = 0.018)和T2加权MRI信号强度(p < 0.001)方面差异显著;AVC在T2加权MRI信号强度(p < 0.001)、肿瘤位置(p = 0.025)和初始肿瘤体积(p < 0.001)方面差异显著。
  • 极高生长组中位RGR为17.5%(IQR 8.3%-44.1%)、中位AVC为1.05(IQR 0.18-3.53)cm³/年;高生长组分别为8.2%(IQR 2.9%-18.6%)和0.33(IQR 0.06-1.66)cm³/年;低生长组分别为3.4%(IQR 1.2%-5.8%)和0.04(IQR 0.02-0.21)cm³/年;组间差异显著(p < 0.001)。
  • 极高生长组5年内典型肿瘤体积增加2.24倍或5.24 cm³,而低生长组即使5年随访期间肿瘤体积变化也很小。

临床怎么用

  • 作者认为这些结果可能使临床医生通过判断病变是否偏离典型生长速度范围来轻松识别需要频繁随访或早期治疗的病变,类似于儿童的生长曲线图。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas are the most common primary intracranial tumors, and their clinical and biological characteristics vary by location. Convexity, parasagittal, and falx meningiomas account for approximately 50%-65% of intracranial meningiomas. Focusing only on these locations, the aim of this study was to determine the typical speed of tumor growth, to assess the growth risk, and to show the possible tumor volume that many lesions can reach after 5 years. METHODS: Patients with radiologically suspected convexity, parasagittal, or falx meningiomas at the authors' institution were studied retrospectively. The relative growth rate (RGR) and annual volume change (AVC) were calculated from MRI at more than 3-month intervals. Based on sex, age, and signal intensity on T2-weighted MRI, the cases were classified into three groups: extremely high-growth, high-growth, and low-growth groups. RESULTS: The data of 313 cases were analyzed. The median RGR and AVC for this entire cohort were 6.1% (interquartile range [IQR] 2.4%-16.0%) and 0.20 (IQR 0.04-1.18) cm3/year, respectively. There were significant differences in sex (p = 0.018) and T2-weighted MRI signal intensity (p < 0.001) for RGR, and T2-weighted MRI signal intensity (p < 0.001), tumor location (p = 0.025), and initial tumor volume (p < 0.001) for AVC. The median RGR and AVC were 17.5% (IQR 8.3%-44.1%) and 1.05 (IQR 0.18-3.53) cm3/year, 8.2% (IQR 2.9%-18.6%) and 0.33 (IQR 0.06-1.66) cm3/year, and 3.4% (IQR 1.2%-5.8%) and 0.04 (IQR 0.02-0.21) cm3/year for the extremely high-growth, high-growth, and low-growth groups, respectively, with a significant difference among the groups (p < 0.001). A 2.24-times, or 5.24 cm3, increase in tumor volume over 5 years was typical in the extremely high-growth group, whereas the low-growth group showed little change in tumor volume even over a 5-year follow-up period. CONCLUSIONS: For the first time, the typical speed of tumor growth was calculated, focusing only on patients with convexity, parasagittal, and falx meningiomas. In addition, the possible tumor volume that many lesions in these locations can reach after 5 years was shown based on objective indicators. These results may allow clinicians to easily detect lesions that require frequent follow-up or early treatment by determining whether they deviate from the typical range of the growth rate, similar to a growth chart for children.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yamada S, Hirayama R, Iwata T, et al. Growth risk classification and typical growth speed of convexity, parasagittal, and falx meningiomas: a retrospective cohort study. J Neurosurg. 2022. PMID: 36115061. doi:10.3171/2022.8.JNS221290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。